Want to see SE:ELIC full AI Analyst Report?
Top Page
Elicera Therapeutics AB
(ELIC)
Select Model
Select Model
Rating:48Neutral
Price Target:
kr3.00
▼(-43.93% Downside)
Action:Reiterated
Date:09/06/26
The score is held down primarily by very weak operating fundamentals (TTM revenue at 0, persistent losses, and substantial cash burn), which elevate execution and financing risk. A debt-free balance sheet provides some stability, while technical indicators are mildly positive in the short term but do not fully offset the longer-term weakness and limited valuation support from negative earnings.
Positive Factors
Debt-free balance sheet
A debt-free balance sheet reduces financial risk and avoids interest or refinancing burdens while the company advances its development programs. This gives management greater flexibility in allocating capital toward research, clinical work, and potential partnering activities over the next several quarters.
Negative Factors
No current TTM revenue
Revenue has deteriorated sharply to zero on a trailing basis, indicating that the company currently lacks a commercial revenue stream to fund operations. Until partnering proceeds, product sales, or development milestones emerge, financial performance remains highly dependent on successful pipeline advancement.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A debt-free balance sheet reduces financial risk and avoids interest or refinancing burdens while the company advances its development programs. This gives management greater flexibility in allocating capital toward research, clinical work, and potential partnering activities over the next several quarters.
Read all positive factors
Elicera Therapeutics AB (ELIC) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr192.20M
Dividend YieldN/A
Average Volume (3M)470.74K
Price to Earnings (P/E)―
Beta (1Y)0.17
Revenue GrowthN/A
EPS Growth14.10%
CountrySE
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.35
Shares Outstanding66,736,374
10 Day Avg. Volume379,117
30 Day Avg. Volume470,735
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)10.19
Price to Sales (P/S)0.00
P/FCF Ratio-11.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.43
Revenue Forecast (FY)N/A
Elicera Therapeutics AB Business Overview & Revenue Model
Company Description
Elicera Therapeutics AB (publ), a Swedish immuno-oncology firm founded in Göteborg in 2014, is dedicated to the clinical development of cell and gene therapies that harness the immune system to combat cancer. Its promising pipeline features severa...
How the Company Makes Money
Elicera Therapeutics primarily aims to generate revenue through (1) out-licensing and partnering of its iTANK platform and/or specific therapeutic programs to other biotechnology or pharmaceutical companies, typically in exchange for upfront payme...
Elicera Therapeutics AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 7.13M | 11.23M | 1.28M | 587.00 |
| Gross Profit | 0.00 | 0.00 | 7.13M | 11.22M | 1.28M | -11.19K |
| EBITDA | -18.03M | -17.40M | -16.82M | -17.09M | -19.43M | -13.11M |
| Net Income | -17.98M | -17.41M | -16.11M | -16.40M | -19.52M | -13.12M |
Balance Sheet | ||||||
| Total Assets | 59.60M | 27.42M | 27.56M | 30.18M | 46.31M | 54.74M |
| Cash, Cash Equivalents and Short-Term Investments | 58.13M | 24.85M | 26.40M | 29.38M | 43.82M | 52.39M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 3.35M | 4.06M | 6.79M | 13.78M | 13.51M | 2.50M |
| Stockholders Equity | 56.25M | 23.36M | 20.77M | 16.40M | 32.80M | 52.24M |
Cash Flow | ||||||
| Free Cash Flow | -25.75M | -21.55M | -23.46M | -14.92M | -8.57M | -14.29M |
| Operating Cash Flow | -25.75M | -21.55M | -23.46M | -14.92M | -8.57M | -14.29M |
| Investing Cash Flow | 0.00 | 1.00K | 0.00 | 483.17K | 0.00 | -1.00K |
| Financing Cash Flow | 44.21M | 20.00M | 20.48M | 0.00 | 0.00 | 55.12M |
Elicera Therapeutics AB Technical Analysis
Positive
5.35
Price Trends
2.66
Positive
2.86
Negative
4.16
Negative
Market Momentum
0.05
Negative
56.03
Neutral
75.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ELIC, the sentiment is Positive. The current price of 5.35 is above the 20-day moving average (MA) of 2.76, above the 50-day MA of 2.66, and above the 200-day MA of 4.16, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 56.03 is Neutral, neither overbought nor oversold. The STOCH value of 75.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ELIC.
Elicera Therapeutics AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | kr497.63M | 2.60 | 63.09% | ― | ― | ― | |
53 Neutral | kr678.44M | -2.28 | ― | ― | 87.23% | 35.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | kr192.20M | -8.14 | -56.09% | ― | ― | 14.10% | |
48 Neutral | kr466.87M | -4.11 | -18.05% | ― | ― | 15.97% | |
43 Neutral | kr1.60B | -3.22 | -99.58% | ― | -87.22% | -70.29% | |
40 Underperform | kr172.73M | -0.02 | -736.08% | ― | -98.81% | 80.33% |
* Healthcare Sector Average
SE:ELIC
Elicera Therapeutics AB
2.83
-3.83
-57.53%
SE:ATORX
Alligator Bioscience AB
0.03
-0.91
-97.21%
SE:BINV
BioInvent International AB
23.75
-5.65
-19.22%
SE:ONCO
Oncopeptides AB
1.75
-3.21
-64.73%
SE:IMMU
Immunicum AB
7.30
0.40
5.80%
SE:CANTA
Cantargia AB
1.73
-0.86
-33.20%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.